KVUE - Kenvue Inc.
AssuredPartners Investment Advisors LLC acquired a new position in shares of Kenvue Inc. (NYSE: KVUE) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 32,710 shares of the company's stock, valued at approximately $625,000. A number of other institutional
B and T Capital Management DBA Alpha Capital Management acquired a new stake in shares of Kenvue Inc. (NYSE: KVUE) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 265,605 shares of the company's stock, valued at approximately $5,076,000. A number of other large investors
Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, and will become a member of Kimberly-Clark's Executive Leadership Team.
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B cost and $1.4B revenue synergy targets.
Kimberly-Clark remains a compelling value and income play, supported by strong brands and resilient consumer demand. KMB trades at a discounted 14.6x forward P/E with a well-covered 4.7% dividend yield and an "A" credit rating. Near-term headwinds include a China diaper controversy and Kenvue integration, but these risks appear priced in.
Shares of Kenvue (NYSE:KVUE | KVUE Price Prediction) closed at $19.18 on August 6, slipping 2.5% after the consumer health giant posted a rare earnings miss.
Kenvue (KVUE), the consumer-health giant behind Tylenol, Neutrogena and Listerine, delivered another quarter of steady growth, but that was not enough to keep i
Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.
Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with the $0.32 consensus estimate.
Kenvue (KVUE) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.29 per share a year ago.
Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, tariffs and currency-related costs squeezed margins.
Kenvue reported higher profit and sales in the second quarter, boosted by higher prices and volumes, as the company continues working to turn around its business ahead of its acquisition by Kimberly-Clark.
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal second quarter ended June 28, 2026. “We delivered our third consecutive quarter of net and organic sales growth, with broad-based gains across every segment and region,” said Kirk Perry, Chief Executive Officer. “We also continued to drive operational efficiencies and increase strategic investment to fuel sustained momentum. Amidst a dynamic consumer and macro environment, our first-half 202.
Cetera Investment Advisers reduced its stake in shares of Kenvue Inc. (NYSE: KVUE) by 24.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 241,189 shares of the company's stock after selling 78,966 shares during the quarter. Cetera Investment
KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.
Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.
KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.
KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a cent.